RTP Mobile Logo
Cancer Educators Slide Library: Case Scenarios and Management of Skin Toxicity
Released October 2010

In the final installment in our online educational activity on dermatological side effects, Dr Milan J Anadkat describes several case studies of patients experiencing dermatologic side effects as a result of systemic anticancer therapy and the strategies employed to ameliorate those toxicities. (Video Content)

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists, hematologists and hematology-oncology fellows.


    • Differentiate between the clinical features of dermatologic side effects associated with the use of capecitabine and EGFR and multikinase (MK) inhibitors.
    • Counsel patients receiving capecitabine, EGFR inhibitors or MK inhibitors about the incidence of treatment-related dermatotoxicities, and offer supportive tactics to reduce the risk and severity of anticipated skin reactions.
    • Employ evidence- and/or consensus-based guidelines when recommending effective topical and systemic interventions for hand-foot skin reactions characteristic of MK inhibitor therapy.
    • Identify patients with classic EGFR inhibitor-associated papulopustular skin rash who may harbor or are particularly prone to acquiring secondary infections at the site of the toxic effect.
    • Facilitate adherence to capecitabine through early recognition and management of palmar-plantar erythrodysesthesia.
    • Appraise the clinical implications of emerging data demonstrating skin rash to be a biomarker of response to EGFR inhibitor treatment.
    • Develop best-practice supportive management algorithms to classify and palliate cancer treatment-induced dermatologic side effects.
    • Recognize the physical and psychosocial challenges faced by patients with moderate to severe dermatotoxicity, and communicate the importance of continued medication compliance.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains a video component. The participant should watch the video content.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Milan J Anadkat, MD

    Assistant Professor
    Division of Dermatology
    Center for Advanced Medicine
    Washington University School of Medicine
    St Louis, Missouri

    Consulting Agreement: Bristol-Myers Squibb Company; Speakers Bureau: Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Amgen Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Bristol-Myers Squibb Company and Genentech BioOncology.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2010
    Expiration date: October 2011

Acknowledge and close

Watch video
(WIFI is recommended for best performance):